Shattuck Labs (NASDAQ:STTK) and Puma Biotechnology (NASDAQ:PBYI) Head to Head Analysis

Shattuck Labs (NASDAQ:STTK) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Shattuck Labs and Puma Biotechnology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	0	0	2	0	3.00
Puma Biotechnology	0	0	1	0	3.00

Shattuck Labs presently has a consensus target price of $20.00, indicating a potential upside of 108.77%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 39.72%. Given Shattuck Labs’ higher probable upside, analysts clearly believe Shattuck Labs is more favorable than Puma Biotechnology.

Risk & Volatility

Shattuck Labs has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.

Insider & Institutional Ownership

58.7% of Shattuck Labs shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 9.9% of Shattuck Labs shares are held by insiders. Comparatively, 22.7% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Shattuck Labs and Puma Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	-5,268.44%	-63.08%	-56.05%
Puma Biotechnology	9.16%	58.21%	10.40%

Earnings and Valuation

This table compares Shattuck Labs and Puma Biotechnology’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1.66 million	273.95	-$87.30 million	($2.05)	-4.67
Puma Biotechnology	$235.60 million	1.03	$21.59 million	$0.46	10.89

Puma Biotechnology has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Summary

Puma Biotechnology beats Shattuck Labs on 9 of the 13 factors compared between the two stocks.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

About Puma Biotechnology

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.